Every other month DMRF Canada publishes Going Forward; our bi-monthly e-newsletter.
What's Making News
Details of the study and eligibility details are available here. Canadian patients are welcome to participate in the study if eligible. The exception for international participants is that while some travel expenses are covered once participants have been enrolled in the study, only certain expenses within the United States can be covered.
Approval is based on the first large-scale neurotoxin trial to demonstrate meaningful functional improvement in pediatric lower limb spasticity
The Ipsen Biopharmaceuticals Canada Inc., the Canadian affiliate of Ipsen (EURONEXT PARIS: IPN) (ADR: IPSEY) today announced that Health Canada has approved DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients two years of age and older.
Click here for the press release.
What is Chucks Run, Walk and Wheel for Dystonia?
The Chuck’s Run, Walk and Wheel 5KM for dystonia is a fun, family-friendly event, hosted at High Park, Toronto on Sunday, June 3, 2018 to raise awareness and funds for dystonia, a neurological movement disorder.
Registration: $39 or you can fundraise $150 and waive your registration fee.
Novel sophisticated research tools are providing investigators new ways to explore the genetics of dystonia. Researchers have the ability to quickly sequence individual genes, analyze whole genomes, and analyze gene expression patterns. Individuals and families who volunteer for genetic studies contribute invaluably to research progress.
A team of investigators led by William Dauer, MD of University of Michigan has made new discoveries about DYT6 dystonia, which affects children. DYT6 dystonia occurs when the body cannot properly produce a protein called THAP1, whose role and function in cells is unknown. Using a mouse model, Dr. Dauer and colleagues discovered that THAP1 is essential for myelination, a process during brain development that forms a protective coating around neurons.